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Abstract: Insomnia is the leading sleep disorder in the US; however, diagnosis is often 
problematic. This pilot study assessed the clinical value of a novel diagnostic insomnia 
questionnaire. The SleepMed Insomnia Index (SMI) was administered to 543 consecutive 
patients and 50 normal control subjects during a pilot study. Mean SMI scores were assessed 
based on subsequent sleep-related diagnoses. The SMI scores for patients with sleep-related 
disorders were signiﬁ  cantly higher than those for the control group (p < 0.001) and highest for 
the 90 patients comprising the insomnia group. Analysis of the SMI scores from the 90 insomnia 
patients indicates a high degree of reliability (Cronbach’s alpha: 0.7). These data support our 
clinical experience with this diagnostic tool which indicates a strong likelihood of disrupted 
nighttime sleep in patients with high SMI scores. Following further validation, the SMI may 
prove to be a valuable tool for evaluating sleep disorders, speciﬁ  cally as an aid in the diagnosis 
of insomnia. The Sleep Matrix is a visual tool that quantiﬁ  es a sleep complaint by combining 
scores from the Epworth Sleepiness Scale (ESS) and the SMI. The SMI measures an insomnia 
component while the ESS is an accepted measure of daytime sleepiness. The Sleep Matrix 
visually displays the complexity of the sleep complaint in an effort to differentiate insomnia 
with differing etiologies from other sleep disorders and measure treatment outcomes. To pilot 
test the Sleep Matrix, the tool was administered to 90 patients with insomnia and to 22 normal 
controls. Plots from the insomnia patients were concentrated into the “insomnia zone” while 
scores from the normal controls were located in the “normal zone” located in the lower left 
quadrant. Additional research using the Sleep Matrix could provide data that the tool could be 
utilized to visually aid the clinician in the diagnosis of unknown sleep complaints.
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Introduction
Estimated to affect as many as 25 million adults, chronic insomnia is the most prevalent 
sleep disorder in America today (Walsh 2004) and is associated with signiﬁ  cant health-
related consequences. The National Institutes of Health (NIH) reports that 50% of 
patients seen in clinical practice today describe symptoms of insomnia; 30% of the 
general population report disrupted nocturnal sleep and 10% of the population has 
an insomnia diagnosis with impaired daytime functioning (NIH 2005). In a survey of 
1000 people with insomnia symptoms (Ancoli-Israel and Roth 1999), 72% of people 
responded “very often” or “sometimes” to the question: how often do you wake up 
feeling drowsy or tired?
The problem worsens with advancing age. Insomnia is estimated to increase by as 
much as 20%–50% in the elderly (>65 years) (NIH 2005), especially among women 
and is often attributed to the onset of menopause. Compared to men, the prevalence of 
insomnia is 1.4 times greater in women under age 45, increasing to 1.7 times greater 
after age 45 (Ohayon 2002). The reasons for the increased frequency of insomnia in Neuropsychiatric Disease and Treatment 2007:3(4) 502
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this population are many and include an increased incidence 
of medical and psychiatric disorders with advanced age and 
greater use of medications which can adversely affect sleep 
(Richardson and Zee 2006).
Compared to people with normal sleep, patients with 
insomnia are more likely to experience anxiety and depres-
sion and suffer other serious consequences, such as work- and 
driving-related accidents (Mitler et al 2000) and an overall 
increase in mortality rate (Kripke et al 2002). The direct 
healthcare costs of insomnia in the US have been estimated 
to be $14 billion annually (Walsh 2004). Considering the 
personal and societal consequences of insomnia, the need 
for early diagnosis and intervention is obvious, although 
not easily achieved. 
Acute insomnia is transient short term or adjustment 
insomnia. The duration of acute insomnia is one night to a few 
weeks and may be related to environmental or occupational 
stress or illness. The acute insomnia typically resolves with 
adaptation or removal of the stressor. Acute insomnia can 
lead to chronic insomnia if left untreated. 
Chronic insomnia is generally defined as difficulty 
initiating or maintaining nocturnal sleep or difﬁ  culty achiev-
ing restorative sleep for longer than one month, associated 
with signiﬁ  cant distress and without obvious relationship 
with other disorders or substance abuse (APA 1994). Chronic 
insomnia can either be primary or co-morbid and waxes 
and wanes over time. Primary insomnia is the term applied 
when no co-existing disorder can be identiﬁ  ed (NIH 2005). 
In addition, primary insomnia often results in other health-
related sequelae and patients may present to their primary 
care physician with major complaints other than insomnia, 
such as daytime sleepiness, fatigue, mood changes (Moul 
et al 2002), or other symptoms which have a negative impact 
on daytime functioning.
 Co-morbid insomnia may be obscured by an underlying 
condition, such as chronic pain, sleep disorders, medications, 
substance abuse, or a host of other medical and psychiatric 
conditions (American Academy of Sleep Medicine 2005). 
Consequently, a diagnosis of insomnia may not be obvious 
and the National Center on Sleep Disorders Research at the 
National Institutes of Health recently recommended that 
secondary insomnia be termed ‘co-morbid insomnia’ rather 
than a symptom of other disorders, emphasizing that large 
numbers of individuals with chronic illness suffer from frag-
mented sleep (NIH 2005). This group has also identiﬁ  ed the 
need for additional research to more clearly deﬁ  ne the nature 
of chronic insomnia and to better characterize its expression 
among various patient populations (NIH 2005).
Since insomnia can occur as a result of varied causes, 
it is essential to evaluate the other differential diagnoses to 
allow successful treatment planning (Chesson 2000). There 
is a high co-morbidity between insomnia and psychiatric 
disorders. Approximately 50% of patients with insomnia 
have a psychiatric diagnosis (Bonnet 1983). It is impor-
tant to differentiate insomnia from these other psychiatric 
or mood disorders. Various sleep disorders can produce 
an insomnia complaint as well including periodic limb 
movement disorder, restless legs syndrome, sleep apnea, 
parasomnias, and/or sleep-related eating disorders. Many 
medical disorders can produce insomnia including asthma, 
COPD, bronchitis, GERD, dementia, Parkinson’s disease, 
rheumatoid arthritis, ﬁ  bromylagia, and hyperthyroidism. 
Often patients may have poor sleep habits/hygiene which 
leads to sleep fragmentation. Symptoms or a history of 
substance or alcohol abuse can have long lasting effects 
on sleep quality requiring clinicians to obtain a history of 
current and past usage. A complete history of prescription 
medication use and over-the-counter medications will 
assess if any medication(s) could be a contributing factor 
in the insomnia complaint.
Circadian rhythm sleep disorders should be considered 
when evaluating patients with insomnia. Homeostatic and 
circadian processes regulate sleep wake cycles (Kilduff 
1993). The homeostatic drives for sleep are driven by the need 
for sleep and increase with the duration of waking (Monk 
2003). Circadian rhythms synchronize sleep and waking 
to the dynamic 24-hour light-dark cycle (Kilduff 1993). 
Behavior affecting this rhythm or physiological abnormalities 
in the regulation of this pattern can lead to sleep disorders 
producing an insomnia complaint. 
The circadian rhythm sleep disorders are jet lag 
syndrome, shift work sleep disorder, delayed sleep phase 
syndrome, advanced sleep phase syndrome, irregular sleep-
wake pattern, and non-24-hour sleep-wake syndrome. Time 
zone change syndrome known as jet lag and shift work sleep 
disorder are extrinsic sleep disorders which occur as a result 
of a behaviorally initiated voluntary mismatch between 
the desired timing of the sleep-wake cycle and circadian 
phase (Wyatt 2004). While the four remaining circadian 
disorders can be referred to as intrinsic sleep disorders which 
presumably result from abnormal functioning of the circadian 
system itself or interaction with sleep homeostasis (Wyatt 
2004). In considering the differential diagnosis of delayed 
sleep phase syndrome, patients will report an inability to 
sleep until several hours or awaken before several hours later 
than they would prefer. Therefore, when attempts are made Neuropsychiatric Disease and Treatment 2007:3(4) 503
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to go to sleep earlier than biologically mandated later hour, 
sleep-onset insomnia is present (Wyatt 2004).
Given that 70% of patients with sleep problems have 
never discussed their symptoms with their physician (Ancoli-
Israel and Roth 1999), it can be challenging for physicians 
to identify patients with insomnia. Insomnia problems are 
complex and multifactorial illustrating the importance of a 
sophisticated and thorough assessment (Edinger 2005). Tools 
that can help identify and quantify an insomnia complaint 
will enable physicians to provide a higher level of care for 
patients. The early identiﬁ  cation and intervention in patients 
with sleep disturbances may prevent the development of 
long-term insomnia (Sateia et al 2000).
Although nocturnal polysomnography is useful for 
diagnosing underlying sleep pathologies, such as sleep-
disordered breathing, it is not indicated for the routine 
evaluation of insomnia (Littner et al 2003). Therefore, 
reaching a diagnosis of insomnia must be based on clinical 
evaluation including patient interviews. A detailed, skilled 
history is the foundation of an adequate evaluation of an 
insomnia complaint (Sateia 2000). The clinician needs 
a working knowledge of the signs and symptoms of the 
spectrum of sleep disorders since these may contribute to 
the insomnia complaint (Chesson 2000). Complete medical 
and psychiatric histories are important to obtain to assess for 
any other co-morbidities impacting the insomnia compliant.  
A sleep log or sleep diary kept by the patient and recording 
their sleep/wake habits for 1–2 weeks is another tool that 
will aid the clinician. The sleep log can incorporate other 
variables such as caffeine, alcohol, nicotine, drugs, and 
circadian inﬂ  uences. Bed partner interviews regarding sleep 
patterns are useful. 
To assist with the diagnosis of sleep disorders, including 
insomnia, several patient questionnaires have been developed 
and validated. The Pittsburg Sleep Quality Index (PSQI) 
is a self-rating scale intended to measure general sleep 
disturbances consisting of 19 items and is often used in 
clinical research trials (Buysse 1988). The Insomnia Severity 
Index is a 7-item scale used to measure perceived sleep 
difﬁ  culties as an outcome measure for insomnia research 
(Bastien 2001). The Athens Insomnia Scale is an 8-item scale 
that evaluates the severity of insomnia as well as its impact on 
daytime well being and functional capacity (Soldatos 2000).  
However, there are many disadvantages to their use, such as 
being long and time-consuming, difﬁ  cult for patients to use or 
having complex scoring systems (Buysse et al 1989; Soldatos 
et al 2000; Violani et al 2004). In contrast, the Epworth 
Sleepiness Scale (ESS) questionnaire is simple to use and 
easy to score (Johns 1991). It is used commonly to detect 
abnormal sleepiness and the need for further evaluation by 
a sleep specialist. Our goal in developing the SMI is to have 
a clinical tool which is simple for patient use, easy to score, 
and quickly provides the clinician insight into the important 
characteristics of the sleep complaint. In addition, the factor 
and global scores can be used in a database as a measure of 
patient outcomes.
 Even in the presence of a decrease in total sleep time, 
patients with insomnia are not typically hypersomnolent. 
The current pathophysiology of insomnia is considered to 
be a hyperaroused state. Therefore, patients usually have 
normal ESS scores. The multiple sleep latency test (MSLT) 
is a sleep test that objectively measures excessive sleepiness 
or sleep need. It is series of 4–5 naps during the day in a 
sleep laboratory measuring latency to sleep onset by EEG. 
Patients who are hypersomnolent usually have shortened 
sleep latencies such as in narcolepsy. The MSLT is not 
used in clinical practice to evaluate an insomnia com-
plaint. In previous research studies of insomnia patients 
when compared with normal controls, MSLT results did 
not show impaired alertness in the insomnia group despite 
having signiﬁ  cantly less nocturnal sleep (Stepanski 1988).   
In the clinical environment patients present with multiple 
sleep complaints that include primary insomnia, co-morbid 
insomnia, circadian rhythm misalignment, and other sleep 
disorders. Since the sleep complaint is often complex and 
associated with co-morbidities, a sleep vital sign using 
the SMI and ESS as a two dimensional matrix, the Sleep 
Matrix, offers a quantitative and differentiating measure 
of the sleep complaint. It is suggested that patients with 
abnormal insomnia scores with elevated ESS scores should 
be evaluated for other medical, psychiatric, or sleep disorder 
diagnoses as well as behavioral factors and pharmacologic 
inﬂ  uences. 
The present report describes the development of a new 
questionnaire, the SleepMed Insomnia Index (SMI), designed 
to quickly measure insomnia symptoms in a simple, standard-
ized way. Similar to the ESS, the SMI is intended to be brief, 
enabling patients to quickly complete it. The SMI question-
naire provides a clinical measure of the characteristics and 
severity of the insomnia complaint. An additional reﬁ  nement 
to the SMI is the simultaneous use of the ESS. Plotting the 
results of these two measuresl the Sleep Matrix, may enable 
clinicians to quickly characterize excessive sleepiness and 
sleep, pathology complaints. These data have previously been 
published in abstract form (Bogan and Turner 2005; Turner 
and Bogan 2005; Turner and Bogan 2005.Neuropsychiatric Disease and Treatment 2007:3(4) 504
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Materials and methods
Questionnaire development
The SMI incorporates features extrapolated from the 
International Classiﬁ  cation of Sleep Disorder (ICSD) 
criteria for the diagnosis of insomnia (American Academy 
of Sleep Medicine 2005) and other clinical features of 
primary and co-morbid insomnia. The questions were 
formulated to address important sleep factors, including 
sleep latency, performance anxiety, ﬁ  rst night effect, the 
frequency of awakenings, sleep re-initiation, total sleep 
time, perceived sleep quality and impact on next day 
function (Table 1). The SMI was designed to be a simple 
tool that can be quickly completed by patients and easily 
scored by clinic staff during the time period prior to the 
ofﬁ  ce visit.
In Question 1, patients provide a global assessment 
of their sleep quality. Problems with sleep initiation and 
performance anxiety are revealed in Questions 2 and 3, 
respectively. The purpose of Question 4 is to determine 
arousal threshold and vigilance by assessing the impact of 
environmental factors on sleep. Question 5 provides insight 
into possible ﬁ  rst night effects, accommodation abnor-
malities, or inadequate sleep hygiene. Sleep continuity is 
assessed in Questions 6 and 7, and Question 9 determines 
whether patients perceive their sleep as adequate. Finally, 
next day consequences of sleep problems are examined in 
greater detail in Questions 8 and 10. A weighting factor 
(0–4) is employed to discriminate patients with no or mini-
mal insomnia symptoms resulting in potential total scores 
ranging from the 10 questions range from 0 (indicating 
no sleep-related problems) to 40 (suggesting signiﬁ  cant 
insomnia-related complaints).
Sleep Matrix development
The Sleep Matrix is a diagnostic tool designed to visually aid 
in the diagnosis of unknown sleep complaints. The SMI is 
primarily designed to characterize the nature and restorative 
quality of nocturnal sleep while the ESS measures the degree 
of daytime sleepiness. ESS scores <10 are considered normal 
while scores >12 indicate severe or pathological sleepiness. 
Ironically, most patients with insomnia complaints display 
normal ESS scores despite their perceived decrease in total 
sleep time or quality. Pathological sleepiness is more likely 
to be the result of sleep disorders such narcolepsy, sleep 
apnea, restless legs syndrome, circadian rhythm disorders, 
and/or sleep deprivation. As described above, co-morbid 
insomnia may be the result of other disease processes and 
psychiatric disorders.
Therefore, the Sleep Matrix was developed to visually 
display the complexity of the sleep complaint in an effort to 
efﬁ  ciently differentiate insomnia with differing etiologies 
from other sleep disorders and measure treatment outcomes. 
The Sleep Matrix plots the SMI scores on the x-axis against 
ESS scores on the y-axis. Six zones within the matrix help 
characterize the sleep complaint. Patients with ESS scores 
<10 fall into three categories in the lower half of the matrix: 
normal patients (SMI scores 0–10), non-sleepy patients 
with nonrestorative sleep (SMI scores 11–20), and insomnia 
patients (SMI scores >20). Patients with ESS scores >12 fall 
into three categories in the upper half of the matrix: sleepy 
Table 1 SleepMed Insomnia Index questionnaire
This is a test to assess, in general, how you are feeling about your sleep. Answer the following questions rating how you feel about your sleep using a 
0–4 point scale with “0” representing no problem with your sleep and “4” representing a severe problem with how you feel about your sleep:
0 = No problem with my sleep
1 = Slight problem with my sleep
2 = Moderate problem with my sleep
3 = Moderately severe problem with my sleep
4 = Severe problem with my sleep affecting all parts of my life
1. Overall, describe your satisfaction with your sleep
2. How easy is it for you to fall asleep?
3. How worried are you that you won’t be able to fall asleep?
4. Are you easily awakened by sounds/noises in the night?
5. When you sleep in a strange place or a bed other than your own, how much trouble do you have trying to fall asleep?
6. Is your sleep disturbed by frequent awakenings?
7.Can you fall back asleep if you awaken during the night?
8. Are you rested the next day after your night’s sleep?
9. Do you think you are getting enough hours of sleep each night?
10.How much does the quality of your sleep affect your next day function (ie, fatigue, mood, irritability)?
Total Score (0–40points)Neuropsychiatric Disease and Treatment 2007:3(4) 505
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patients (SMI scores of 0–10), sleepy patients with nonrestor-
ative sleep (SMI scores of 11–20), and sleepy patients with 
sleep disruption/insomnia (SMI scores >20). Patients with 
SMI/ESS intercepts in the upper half of the matrix will need 
further clinical correlation for the presence of an underlying 
sleep disorder. As ESS scores ranging from 10–12 indicate 
only moderate sleepiness, patients falling into this “grey 
zone” require further clinical assessment.
Assessment of SleepMed Insomnia 
Index (SMI)
The SMI was administered to 543 consecutive adult patients 
who presented to our clinic for evaluation of sleep complaints 
as a 2-month pilot project. Each patient completed the self-
administered questionnaire prior to the initial examination by 
a Board Certiﬁ  ed Sleep Physician. Patients were instructed 
to complete the questionnaire by considering how they feel 
about their sleep quality generally and were encouraged to 
avoid focusing on a recent night of poor quality sleep. No 
patient was excluded from the pilot study.
Each patient underwent a complete history, physical 
examination and a nocturnal polysomnogram if deemed 
necessary by the physician. The ﬁ  nal diagnosis was made 
using established ICSD criteria (American Academy 
of Sleep Medicine 2005). The physician was blinded to 
the results of the SMI score until the examination was 
completed and a patient diagnosis had been recorded by 
the physician on the SMI score sheet. The scores sheets 
were collected for later correlation of SMI scores with sleep 
disorder diagnoses. 
For the purpose of this initial SMI assessment, 
evaluated patients consisted of patients with both 
undiagnosed sleep disorders and previously-diagnosed 
insomnia for which some patients were currently receiving 
treatment with zolpidem. The SMI was also administered 
to a group of 50 control subjects with no history of any 
sleeping problems, use of medications known to affect 
sleep, or variable shift work. 
Statistical analysis
Means and standard deviations are reported for the groups. 
Analysis of variance (ANOVA) was used to measure 
between-group differences. Bartlett’s test for data homogene-
ity of variances was calculated, and SMI question reliability 
was tested using Cronbach’s alpha with signiﬁ  cance was 
accepted at ≤0.7. Independent t-tests assessed signiﬁ  cant 
differences between data sets: signiﬁ  cance was accepted at 
p < 0.001.
Results
Insomnia questionnaire
The SMI scores were divided into 10 diagnostic categories 
to facilitate analysis and comparison. The largest subgroup 
in the sample was patients with obstructive sleep apnea, and 
this group was sub-divided into those on continuous positive 
airway pressure therapy (CPAP) and those not on CPAP. 
Patients reported a sleep complaint secondary to co-morbid 
processes including ﬁ  bromyalgia, pain and depression/mood 
disorders. Due to small patient numbers, less common sleep 
disorders such as REM behavior disorder, nocturnal eating 
syndrome, and shift work sleep disorder were placed into a 
single category.
The demographic characteristics of the study par-
ticipants are provided in Table 2. The sample was fairly 
homogenous in composition by age. The mean age of 
insomnia patinets was 51 (range 21–86 years). The mean 
age of other groups was similar except for patients with 
narcolepsy (40 years), idiopathic hypersomnia (46 years), 
and other sleep disorders (47 years). The mean age of the 
50 control subjects controls was 38. The composition of
the sample by sex follows patterns previously reported in 
the published literature for the various diagnoses. There 
was a higher percentage of women (64%) than men (36%) 
among patients with insomnia. 
For the primary assessment of validity, the degree 
to which the SMI detected clinically distinct differences 
between the various patient groups and normal controls 
was assessed. Thus, the diagnoses based upon the structured 
clinical interviews using ICSD criteria provide the “gold 
standard.” 
Means and standard deviations for the SMI scores for 
patients with various sleep-related disorders are summarized 
in Table 2. Overall, SMI scores were signiﬁ  cantly higher 
than the scores in the control group scores (p < 0.001). 
Notably, the mean SMI score for patients diagnosed with 
insomnia group was 31 and was signiﬁ  cantly higher than 
mean scores in other groups (generally <20; p < 0.001) with 
the exception of the pain group which contained only small 
numbers. Reliability of the tool was assessed for the 90 
insomnia patients with Cronbach’s alpha = 0.7. Mean scores 
were higher for the pain (N = 4), ﬁ  bromyalgia (N = 12), and 
depression/mood disorder groups (N = 5), supporting an 
association between these illnesses and insomnia; however, 
the patient numbers in these groups were small and these 
results may not be representative of the entire patient 
population. Bartlett’s Test for homogeneity of variances was 
signiﬁ  cant (Chi-square = 78, DF = 10, p < 0.001).Neuropsychiatric Disease and Treatment 2007:3(4) 506
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Sleep Matrix
SMI and ESS scores from the 90 patients with insomnia 
(some of the plots represent treated insomnia patients) were 
plotted on a Sleep Matrix with 22 normal controls, revealing 
distinctly different patterns. Plots of the insomnia patients 
were concentrated in the “insomnia zone” in the lower-right 
corner and a few revealed sleepiness with disrupted sleep 
(upper-right corner); however, none were in the “normal 
zone” (Figure 1). In contrast, most all of the plots for the 
normal controls were located in the lower-left “normal zone” 
(Figure 2). 
Assessment of the SMI and Sleep Matrix 
in treated insomnia patients
To assess the potential utility of the SMI tool as an outcome 
measure, it was administered to 17 consecutive adult patients 
who were undergoing treatment for their insomnia during the 
same 2-month period. Each patient was previously diagnosed 
by a Board Certiﬁ  ed Sleep Physician with primary (idio-
pathic) insomnia using ICSD criteria (American Academy of 
Sleep Medicine 2005) for which they were being treated with 
zolpidem. For the purpose of this preliminary SMI assess-
ment, each patient completed the SMI questionnaire while 
receiving nightly zolpidem. Immediately after completing 
the questionnaire, patients were asked complete the SMI 
again while estimating the quality of their nighttime sleep 
and daytime functioning prior to receiving treatment for their 
insomnia. To permit repeat testing, a control group of 22 
different subjects with no history of any sleeping problems, 
use of medications known to affect sleep, or variable shift 
work was also administered the SMI. The demographic 
characteristics of these patients and subjects are summarized 
in Table 2.
While taking zolpidem, the mean SMI and ESS scores 
for the 17 patients with insomnia were 11.5 and 4.9, 
respectively, and were similar to the 22 controls with 
SMI and ESS scores of 4.9 and 4.5, respectively. When 
the insomnia patients completed the SMI again while 
recalling their pre-treatment condition, the mean score 
was 34. The pre- and post-treatment SMI scores for the 
17 insomnia patients were then plotted against their ESS 
scores. The pre-treatment intercepts were concentrated in 
the lower-right corner, indicating a high degree of sleep 
disruption/insomnia but little daytime sleepiness (Figure 3). 
A few intercepts in the upper right corner suggest daytime 
sleepiness may have previously been worse for some 
patients. Treatment with zolpidem resulted in a left-ward 
shift in the intercepts, which now compare favorably with 
the 22 control subjects.
Discussion
While signiﬁ  cant advances have been made in the treatment 
of insomnia, the identiﬁ  cation of patients with insomnia often 
remains problematic. Many insomnia patients present with 
an assortment of other medical complaints and physicians 
may not always associate their presenting symptoms with 
insomnia. The SMI was designed to quickly evaluate patients 
for insomnia and other potential sleep disturbances. Based on 
the patient SMI questionnaire scores, clinicians can structure 
patient interviews to more quickly focus on any potential 
sleep problems identiﬁ  ed by the questionnaire.
All of the patients included in this report presented with 
an existing or subsequently diagnosed sleep disorder and 
demonstrated mean SMI scores which were considerably 
higher than the 50 control subjects. The SMI scores for the 
90 insomnia patients were the highest observed with a mean 
Table 2 Sample characteristics
Disorder N  Age  Male  Female  Mean SMI
    mean (range)  N (%)  N (%)  score (SD)
Insomnia  90  51.2 (21–86)  32 (36)  58 (64)  31 (5)
OSA on CPAP  158  56.0 (28–84)  99 (63)  59 (37)  12 (8)
OSA not on CPAP  127  52.3 (22–90)  74 (59)  53 (41)  17 (9)
Narcolepsy  39  39.9 (18–67)  16 (41)  23 (59)  17 (9)
Idiopathic hypersomnia  66  45.9 (13–77)  16 (24)  50 (76)  13 (8)
Restless legs syndrome  20  59.8 (33–82)  7 (35)  13 (65)  17 (9)
Fibromyalgia  12  53.0 (39–72)  0  (0)  12 (100)  21 (10)
Depression/mood disorder  5  55.0 (51–61)  2 (40)  3 (60)  24 (10)
Pain  4  58.8 (48–76)  1 (25)  3 (75)  31 (12)
Other sleep disorder  22  47.0 (17–80)  13 (59)  9 (41)  13 (8)
Control 50  37.7 (23–48)  14 (28)  36 (72)  5 (3)
Abbreviations: CPAP, continuous positive airway pressure therapy.Neuropsychiatric Disease and Treatment 2007:3(4) 507
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of 31 while the mean scores in most of the other groups were 
below 20. Consistent with our clinical experience with the 
questionnaire, we believe the SMI identiﬁ  es a high likelihood 
of signiﬁ  cant sleep disruption in patients with SMI scores 
greater than 20. Pain, ﬁ  bromyalgia and depression are also 
disorders characterized by disrupted sleep and patients with 
these diagnoses were also found to have higher mean SMI 
scores (range 21–31); however, since there were only 5 
patients with depression and 4 with pain, we suspect these 
SMI scores may not be representative of the these patient 
groups. 
The data obtained from the insomnia patients and normal 
control subjects also indicates the Sleep Matrix can discrimi-
nate between primary insomnia patients and normal controls 
with a reasonable degree of certainty. The ESS has previously 
been used to assess patients with insomnia (Johns 1997); 
however, patients with idiopathic insomnia often suffer 
from states of hypervigilance, displaying normal ESS scores 
(Reidel and Lichstein 2000), as demonstrated by many of 
the patients in our study. For these patients, plotting the ESS 
Figure 1 Insomnia/Sleep Matrix plots. Sleep Matrix plots for an additional 90 patients with insomnia. Most of the plots are located in the lower right-hand corner. Some of 
the insomnia patients also reported sleepiness along with disrupted sleep. None of these patients are in the normal zone.
and SMI scores on the Sleep Matrix may enable clinicians to 
quickly identify the problem and consider therapeutic options 
for managing their condition.
Excessive sleepiness is generally not a feature of primary 
insomnia and when present, frequently suggests the presence 
of other sleep disorders (Sateia et al 2000). Patients with 
ESS scores of greater than 10 need clinical correlation as to 
the presence of other underlying sleep disorders. The SMI 
and the Sleep Matrix may help physicians determine when 
another underlying sleep disorder may be present, signal-
ing the need for a formal sleep study. Speciﬁ  cally, patients 
with ESS/SMI scores falling in the upper half of the Sleep 
Matrix may require referral to a sleep specialist for further 
evaluation, especially if initial treatment does not result in 
improvement.
The use of the Sleep Matrix indicates signiﬁ  cant differences 
between patients treated for insomnia and estimates of their prior 
untreated condition. Thus, the Sleep Matrix may also be a useful 
indicator of treatment response. For example, the Sleep Matrix 
may be useful in assessing the clinical status of patients with 
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Figure 2 Normal controls. Sleep Matrix plots for 22 normal controls are concentrated in the lower-left corner. 
Figure 3 Example of utility of Sleep Matrix in a group of 17 treated insomnia patients. Sleep Matrix plots for 17 insomnia patients. When the SMI scores estimating the 
quality of nighttime sleep prior to drug treatment were plotted against ESS scores, most intercepts are located in the lower-right corner, indicating a high degree of sleep 
disruption but little daytime sleepiness. During drug therapy for insomnia, the SMI scores were plotted against ESS scores. The SMI/ESS intercepts shifted to the left of the 
matrix, indicating decreased sleep disruption and greater similarity with the plots for the 22 control patients.
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insomnia during clinical trials, as the measure of therapeutic 
outcomes of these trials remains challenging (Morin 2002).
It should be noted that normal patients generally have ESS 
scores of <10 while ESS scores >12 indicate pronounced, 
even pathological sleepiness. Thus, scores in the range of 
10–12 constitute a “grey zone” indicating that the patient may 
have some symptoms of sleepiness but no adverse effects on 
quality of life. Further clinical evaluation is required for these 
patients as other medical conditions or poor sleep hygiene 
may be responsible for their sleepiness.
The goal of future, prospective studies will be to further 
validate the SMI and the Sleep Matrix with larger patient num-
bers in other geographical locations with various sleep disor-
ders, and to correlate the results with other validated measures, 
such as the Clinical Global Impression of Severity and Change 
(Hajak et al 2002), ultimately permitting further assessment of 
sleep disorders and the measurement of treatment outcomes. 
Factor analysis will be examined to characterize speciﬁ  c sleep 
disorders. Although Cronbach’s alpha indicate the SMI is a 
reliable tool, retest reliability will also be scrutinized. 
Conclusion
The results of this pilot study suggest that the SMI demon-
strates sensitivity to discriminate normal from abnormals 
but more closely examines insomnia severity, characteristics 
or types. Both the SMI and the Sleep Matrix may be useful 
clinical tools for the diagnosis of insomnia. Indications for 
nocturnal polysomnography may be guided by these results. 
Future studies will attempt to validate these measures of sleep 
quality with the ultimate goal of improving the diagnosis and 
care of patients with insomnia and other sleep disorders.
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